SAN FRANCISCO, CA--(Marketwired - August 24, 2017) - A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk.

Included in this article is: RepliCel Life Sciences Inc. (TSX VENTURE: RP) (OTCQB: REPCF)

On Aug. 16, analyst Douglas Loe with Echelon Wealth Partners commented on RepliCel Life Sciences Inc.'s (TSX VENTURE: RP) (OTCQB: REPCF) participation in the ThawSTAR Early Adopter Program, "a cell processing system developed by private CA-based firm Medcision that works with companies in cell therapy processing, for which one of the challenges to sustaining cell viability is managing freeze-thaw cycles." He noted that RepliCel will "specifically use Medcision's ThawSTAR AT2 Automated Cell Thawing Systems (the firm has several models & accessories) for upcoming Phase II trials using RP's non-bulbar dermal sheath fibroblast therapy RCS-01, aimed at the treatment of skin rejuvenation (the Phase I trial will be completed this month; interim results reported back in Apr/17)."

Continue reading this article: Analyst Says Cell Therapy Company's Move Decreases Risk

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following companies mentioned in this article are billboard sponsors of Streetwise Reports: RepliCel Life Sciences. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

Please see the end of the article for the complete disclosures: Analyst Says Cell Therapy Company's Move Decreases Risk